Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?
Department of Medicine, Division of Cardiovascular Medicine; Department of Population and Quantitative Health Sciences
Cardiology | Cardiovascular Diseases | Health Services Administration | Translational Medical Research
BACKGROUND: Dual antiplatelet therapy (DAPT) is a mainstay treatment for hospital survivors of an acute myocardial infarction (AMI). However, there are limited data on the prescribing patterns of DAPT among patients hospitalized with AMI during recent years.
OBJECTIVE: To examine decade-long trends (2001-2011) in the use of DAPT versus antiplatelet monotherapy and patient characteristics associated with DAPT use.
METHODS: The study population consisted of 2389 adults hospitalized with an initial AMI at all 11 central Massachusetts medical centers on a biennial basis between 2001 and 2011. DAPT was defined as the discharge use of aspirin plus either clopidogrel or prasugrel. Logistic regression analysis was used to identify patient characteristics associated with DAPT use.
RESULTS: The average age of the study population was 65 years, and 69% of patients were discharged on DAPT. The use of DAPT at the time of hospital discharge increased from 49% in 2001 to 74% in 2011; this increasing trend was seen across all age groups, both sexes, types of AMI, and in those who underwent a PCI. After multivariable adjustment, patients 65-74 years old (adjusted odds ratio (aOR)=0.53, 95% CI: 0.36-0.80) and those who underwent coronary artery bypass surgery (aOR=0.11, 95% CI: 0.07-0.18) were less likely to have received DAPT, while men (aOR=14.60, 95% CI: 10.66-19.98) and those who underwent cardiac catheterization and stenting (aOR=14.60, 95% CI: 10.66-19.98) were significantly more likely to have received DAPT at discharge than respective comparison groups.
CONCLUSIONS: Between 2001 and 2011, the use of DAPT increased markedly among patients hospitalized with AMI. However, a significant proportion of patients were not discharged on this therapy. Greater awareness is needed to incorporate DAPT into the management of patients hospitalized with AMI.
Acute myocardial infarction, Aspirin, Clopidogrel, Dual antiplatelet therapy, Prasugrel, UMCCTS funding
DOI of Published Version
Hariri E, Lessard D, Gore J, Rade J, Goldberg R. Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction? Cardiovasc Revasc Med. 2020 Feb;21(2):182-188. doi: 10.1016/j.carrev.2019.04.024. Epub 2019 May 2. PMID: 31129036; PMCID: PMC6824980. Link to article on publisher's site
Cardiovascular revascularization medicine : including molecular interventions
Hariri E, Lessard DM, Gore JM, Rade JJ, Goldberg RJ. (2020). Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?. UMass Center for Clinical and Translational Science Supported Publications. https://doi.org/10.1016/j.carrev.2019.04.024. Retrieved from https://escholarship.umassmed.edu/umccts_pubs/211